LSB Stock Overview
A biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
LakeShore Biopharma Co., Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.57 |
52 Week High | US$1.50 |
52 Week Low | US$0.35 |
Beta | 0.62 |
11 Month Change | -31.78% |
3 Month Change | -32.35% |
1 Year Change | -58.42% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -91.42% |
Recent News & Updates
LakeShore Biopharma Co., Ltd (NASDAQ:LSB) Looks Inexpensive After Falling 36% But Perhaps Not Attractive Enough
Jun 25Little Excitement Around YS Biopharma Co., Ltd.'s (NASDAQ:YS) Revenues
May 08Shareholder Returns
LSB | US Biotechs | US Market | |
---|---|---|---|
7D | -6.6% | -2.6% | 0.7% |
1Y | -58.4% | 8.8% | 21.5% |
Return vs Industry: LSB underperformed the US Biotechs industry which returned 10.4% over the past year.
Return vs Market: LSB underperformed the US Market which returned 20.5% over the past year.
Price Volatility
LSB volatility | |
---|---|
LSB Average Weekly Movement | 15.2% |
Biotechs Industry Average Movement | 10.2% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: LSB's share price has been volatile over the past 3 months.
Volatility Over Time: LSB's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 754 | Dave Chenn | www.ysbiopharm.com |
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines.
LakeShore Biopharma Co., Ltd Fundamentals Summary
LSB fundamental statistics | |
---|---|
Market cap | US$111.19m |
Earnings (TTM) | -US$45.88m |
Revenue (TTM) | US$74.83m |
1.4x
P/S Ratio-2.3x
P/E RatioIs LSB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LSB income statement (TTM) | |
---|---|
Revenue | CN¥544.09m |
Cost of Revenue | CN¥107.51m |
Gross Profit | CN¥436.58m |
Other Expenses | CN¥770.14m |
Earnings | -CN¥333.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.77 |
Gross Margin | 80.24% |
Net Profit Margin | -61.31% |
Debt/Equity Ratio | 115.7% |
How did LSB perform over the long term?
See historical performance and comparison